A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; Lurbinectedin (Primary) ; Topotecan; Topotecan
Indications Small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms LAGOON
Sponsors PharmaMar

Most Recent Events

04 Jun 2024 According to PharmaMar media release, presented data from this trial at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States.
30 Apr 2024 Planned End Date changed from 1 Jun 2025 to 1 Apr 2026.
30 Apr 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Apr 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight